Bristol-Myers Squibb ( (BMY) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol-Myers Squibb shares came under pressure as investors focused on ongoing weakness in older, legacy drugs that continue to lose ground to generics, overshadowing growth elsewhere in the portfolio. The mixed picture raised doubts about how quickly new treatments can fully offset those declines.
Still, the company reiterated confidence in its longer-term outlook, keeping its 2026 revenue target at $46–47.5 billion and maintaining guidance on margins and expenses. Management also highlighted expectations for renewed Eliquis growth in 2026 and pointed to several pivotal pipeline readouts as future potential catalysts.
More about Bristol-Myers Squibb
YTD Price Performance: 9.15%
Average Trading Volume: 12,287,601
Technical Sentiment Signal: Strong Buy
Current Market Cap: $117.6B
For further insights into BMY stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.